Hereditary Cancer Testing Market Publication Month: Sep 2019 | Report Code: TIPRE00006578 | No. of Pages: 171 | Category: Biotechnology | Status: Published
Hereditary Cancer Testing Market to 2027 - Global Analysis and Forecasts By Diagnosis Type (Biopsy, Imaging); Technology (Sequencing, PCR, Microarray); End User (Hospital, Clinics, Diagnostic Centers), and Geography
E-Mail : sales@theinsightpartners.com
Hereditary Cancer Testing Market Publication Month: Sep 2019 | Report Code: TIPRE00006578 | No. of Pages: 171 | Category: Biotechnology | Status: Published
Introduction:
According to a new market research study titled 'Hereditary Cancer Testing Market to 2027 – Global Analysis and Forecasts by Diagnosis Type, Technology, and End User'. The global hereditary cancer testing market is expected to reach US$ 9,840.52 Mn in 2027 from US$ 3,967.74 Mn in 2018. The market is estimated to grow with a CAGR of 11.1% from 2019-2027. The report highlights the trends prevalent in the global hereditary cancer testing market and the factors driving the market along with those that act as deterrents to its growth. The market for hereditary cancer testing is expected to grow, owing to factors such as increasing prevalence of hereditary cancer and growing awareness about hereditary cancer have been boosting the market over the years. In addition, growing demand for noninvasive methods of detection are likely to have a positive impact on the growth of the market in the coming years.
E-Mail : sales@theinsightpartners.com
Hereditary Cancer Testing Market Publication Month: Sep 2019 | Report Code: TIPRE00006578 | No. of Pages: 171 | Category: Biotechnology | Status: Published
Market Insights Increasing Prevalence of Hereditary Cancer Cancer is a genetic disorder caused due to definite variations in genes that govern cell functioning, particularly affecting their growth and replication. Hereditary genetic mutations are the cause of ~5– 10% of all cancers. The researchers have related mutations in particular genes with more than 50 hereditary cancer syndromes affecting individuals in developing certain cancers. According to the World Health Organization, cancer caused ~9.6 million deaths worldwide in 2018. Further, as per the prediction of the National Cancer Institute, in 2018, ~1,735,350 new cancer cases would be diagnosed in the US. The increasing prevalence of breast cancer in the world is a huge concern. As per the World Health Organization, ~2.09 million cases of breast cancer were reported globally in 2018. However, according to breastcancer.org, in 2018, over 3.1 million women in the US were reported with a history of breast cancer. Furthermore, ~5–10% of breast cancers are related to the mutated genes inherited from parents. The variations in the BRCA1 and BRCA2 genes are prevalent. Women with a BRCA1 mutation have ~72% lifetime risk of developing breast cancer, while those with the BRCA2 mutation have ~69% risk of the same. Hence, with the rising occurrence of cancer, need for their early detection is also rising around the world. Hence, the increasing prevalence of cancer drives the steady growth of the hereditary cancer testing market.
E-Mail : sales@theinsightpartners.com
Hereditary Cancer Testing Market Publication Month: Sep 2019 | Report Code: TIPRE00006578 | No. of Pages: 171 | Category: Biotechnology | Status: Published
Growing Awareness about Hereditary Cancer Although, the genetic testing of various metabolic liabilities of cancer is clinically accessible, the available data suggest that a limited population is aware about these tests. The awareness regarding hereditary cancer conditions is growing due to various efforts made by the government. In the past decade, public medical, health, and scientific communities invested in spreading awareness regarding hereditary cancer conditions, with a major focus on hereditary cancer risk, family history, and genetic testing for inherited cancer liability. Direct-to-consumer (DTC) publicity of cancer genetic testing and federal regulations of genetic information have been other factors driving cancer genetic testing awareness among people. For instance, Myriad Genetics Laboratories, Inc. (Myriad), launched various DTC campaigns in major cities in US in the past decade. Moreover, multiple companies provide genomic profiling services for health assessment, including cancer risk prediction. Thus, increasing awareness regarding genetic cancer would enhance the demand for the diagnostic tests, along with improving the quality and efficacy of hereditary cancer testing during the forecast period. Strategic Insights There have been limited developments made in the hereditary cancer testing market during recent years. However, growth strategies such as approvals, collaborations, and partnerships have been witnessed in the market of hereditary cancer testing. For instance, in February 2019, Hologic, Inc. received the CE Mark to the LOCalizer wireless radio frequency identification (RFID) breast lesion localization system. The approval enhances the portfolio of the company. Also, during October 2018, Cancer Genetics entered into collaboration with Cellaria, LLC. The aim of the collaboration is to manufacture precision medicine tools and platform technologies to support new cancer therapeutics. E-Mail : sales@theinsightpartners.com
Hereditary Cancer Testing Market Publication Month: Sep 2019 | Report Code: TIPRE00006578 | No. of Pages: 171 | Category: Biotechnology | Status: Published
The List of Companies
• • • • • • • • • •
Hologic Inc. Koninklijke Philips N.V. Quest Diagnostics Incorporated Myriad Genetics, Inc. Cancer Genetics Inc. Invitae Corporation Myogenes Strand Life Sciences Pvt. Ltd. Pathway Genomics Corporation CENTOGENE AG
Get Sample PDF Brochure
E-Mail : sales@theinsightpartners.com